- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02896218
Therapeutic Monitoring of Vancomycin in Critical Ill Patients: a Registry (VCMTDMinCI)
Studieöversikt
Detaljerad beskrivning
Vancomycin is a glycopeptide antibiotic that is the first line antibiotics for the treatment of serious gram-positive infections involving methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin use is associated with several adverse events, including nephrotoxicity and ototoxicity. Its therapeutic window is narrow, so there is a need to monitor serum vancomycin concentration in clinical practice, especially in the critically ill patients. Moreover, the Chinese vancomycin TDM guideline recommended that vancomycin dosage should be administered and adjusted individually based on population pharmacokinetic(PPK) and Bayesian methods. However, there is a gap between clinical practice and the guideline. So far, few studies have investigated the clinical outcomes of the dosage strategy that vancomycin dosage is administered and adjusted individually using PPK and Bayesian methods. Pharmacists could provide the vancomycin individualized dosing service by joining the ICU multidisciplinary team. The objective of this study is to investigate the effectiveness, safety and economics of the vancomycin individualized dosing service provided by pharmacists.
This is a single-center, ambispective cohort study. Patients from the retrospective and prospective cohort will be divided into 2 groups by exposure. The exposure is whether patients received pharmacists' consultation. Patients who meet the inclusion and exclusion criteria will be included in our registry. As a non-intervention study, these information as below will be collected: basic demographics, diagnosis, the initial dosage regimen and adjusted strategy of vancomycin, combined special treatment and outcomes.
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studieorter
-
-
Beijing
-
Beijing, Beijing, Kina, 100191
- Rekrytering
- Peking University Third Hospital
-
Kontakt:
- Qinggang Ge, M.D.
- E-post: qingganggelin@126.com
-
Kontakt:
- Yingying Yan, Ph.D.
- E-post: yanyingying89@163.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
The prospective cohort: all patients in this cohort will receive pharmacist consultation when prescribed vancomycin.
The retrospective cohort: patients in this cohort received usual care from JAN 2010 to MAR 2015; patients in this cohort received pharmacist consultation from APR 2016 to JUL 2016.
Beskrivning
Inclusion Criteria:
- Admitted to intensive care unit(ICU), Peking University Third Hospital since JAN 2010.
- Receiving vancomycin therapy for 72 hours or more.
- Aged ≥ 18 years.
Exclusion Criteria:
- Administration of vancomycin in non-intravenous access.
- Life expectancy of less than 24 hours.
- Pregnancy women.
- Presence of immunodeficiency.
- Presence of hematological disorder.
- Written informed consent not obtained in the prospective cohort.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Pharmacist consulting group
When physicians make the decision that patients need to prescribe vancomycin or need dose adjustment, they will call for a pharmacist consultation.
Pharmacists will provide the initial regimen based on PPK methods if applicable, otherwise give the suggestion of the initial dosage according to guidelines.
Also, pharmacists will give suggestions on the time of sampling for serum concentration measurement.
For dosage adjustment, pharmacists will be informed the results of serum vancomycin concentration, and then make a calculation using Bayesian estimation to determine whether there is a necessity to change the dosing regimen.
Pharmacists will follow the patients until they discharge.
|
Pharmacists consultation of vancomycin individualized dosing strategy
|
Usual care group
Empirical use of vancomycin without pharmacists consultation.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
The rate of treatment failure
Tidsram: 2016-9 to 2018-1
|
2016-9 to 2018-1
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
All cause mortality
Tidsram: 2016-9 to 2018-1
|
2016-9 to 2018-1
|
|
Mortality caused by infections
Tidsram: 2016-9 to 2018-1
|
2016-9 to 2018-1
|
|
Mortality caused by gram-positive infections
Tidsram: 2016-9 to 2018-1
|
2016-9 to 2018-1
|
|
Adverse events related to vancomycin
Tidsram: 2016-9 to 2018-1
|
2016-9 to 2018-1
|
|
Nephrotoxicity related to vancomycin
Tidsram: 2016-9 to 2018-1
|
According to KDIGO, AKI is defined by any of the following:
All adverse events will be assessed and analyzed with WHO-UMC causality criteria by investigators. Adverse events related to vancomycin, especially nephrotoxicity, will be analyzed. |
2016-9 to 2018-1
|
Cost-effectiveness of pharmacist intervention
Tidsram: 2016-9 to 2018-1
|
The outcome is the incremental cost of preventing one treatment failure infection-related mortality or nephrotoxicity.
|
2016-9 to 2018-1
|
Duration of using ventilator
Tidsram: 2016-9 to 2018-1
|
2016-9 to 2018-1
|
|
Vancomycin dosage
Tidsram: -2016-9 to 201
|
-2016-9 to 201
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Qinggang Ge, M.D., Peking University Third Hospital
Publikationer och användbara länkar
Allmänna publikationer
- Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009 Nov;29(11):1275-9. doi: 10.1592/phco.29.11.1275.
- Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, Li DK, Liu YN, Yang KH, Zhang YY, Zhai SD; Guideline Steering Group, the Guideline Development Group and the Guideline Secretary Group. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016 Nov;71(11):3020-3025. doi: 10.1093/jac/dkw254. Epub 2016 Jul 11.
- Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, Okada K, Igarashi M, Kobayashi M, Hamada Y, Kimura M, Nishi Y, Tanigawara Y, Kimura T. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013 Jun;19(3):365-80. doi: 10.1007/s10156-013-0599-4. Epub 2013 May 15. No abstract available.
- Pea F, Bertolissi M, Di Silvestre A, Poz D, Giordano F, Furlanut M. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents. 2002 Nov;20(5):326-32. doi: 10.1016/s0924-8579(02)00188-7.
- Smith C, Burley C, Ireson M, Johnson T, Jordan D, Knight S, Mason T, Massey D, Moss J, Williams K. Clinical trials of antibacterial agents: a practical guide to design and analysis. Statisticians in the Pharmaceutical Industry Working Party. J Antimicrob Chemother. 1998 Apr;41(4):467-80. doi: 10.1093/jac/41.4.467.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CM-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kritiskt sjuk
-
National Taiwan University HospitalAvslutadNeurokirurgi, Critical Ill
Kliniska prövningar på Pharmacists consultation
-
American Institutes for ResearchWisconsin Center for Education Research; University of Nebraska College...RekryteringKänslomässiga störningarFörenta staterna
-
Saint John's Cancer InstituteIndragenCancer | Vårdgivare | Kliniska testerFörenta staterna
-
Istanbul University - Cerrahpasa (IUC)Marmara University; Prof. Dr. Cemil Tascıoglu Education and Research Hospital...Avslutad
-
Stony Brook UniversityOkänd
-
Medical University of LublinAvslutadÖveraktiv blåsa | Urininkontinens | Ansträngningsinkontinens | TrängningsinkontinensPolen
-
Koç UniversityHar inte rekryterat ännuLivskvalité | Inkontinens, Urge | Inkontinens Stress
-
The University of Texas Health Science Center,...OkändSjälvförsummelseFörenta staterna
-
Center for Primary Care and Public Health (Unisante)...University of Lausanne Hospitals; Neuchâtel Psychiatry Centre (CNP)Har inte rekryterat ännuLivskvalité | Problem med psykisk hälsa | Samarbete | Psykosomatiska störningar | Läkar-patient relation | Depression/ångest | Patienter Levde ErfarenheterSchweiz
-
Memorial Sloan Kettering Cancer CenterAvslutadLymfom | Benmärgstransplantation | GI Cancer | GU CancerFörenta staterna